When human platelets are incubated with 500 nM-PAF-acether (platelet-activating factor. 1 -O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) under equilibrium conditions (60 min, 22°C, non-stirred suspensions), two classes of fibrinogen binding sites are exposed: one class with a high affinity [Kd (7.2+2.1) x 10-8 M 2367 + 485 sites/platelet, n = 9] and one class with a low affinity [Kd (5.9 + 2.4) x1O-7 M, 26972+8267 sites/platelet]. Preincubation with inhibitors of cyclo-oxygenase (acetylsalicylic acid, indomethacin) or thromboxane synthetase (UK 38.485) completely abolishes high-affinity binding, leaving low-affinity binding unchanged. In contrast, ADP scavengers (phosphocreatine/creatine kinase or phosphoenol pyruvate/pyruvate kinase) completely prevent low-affinity binding, leaving high-affinity binding unaltered. Initial binding studies (2-10 min incubation) confirm these findings with a major part of the binding being sensitive to ADP scavengers, a minor part sensitive to indomethacin and complete blockade with both inhibitors. Increasing the temperature to 37°C decreases the number of low affinitybinding sites 6-fold without changing high-affinity binding. Aggregation, measured as the rate of single platelet disappearance, then depends on high-affinity binding at 10 nM-fibrinogen or less, whereas at 100 nM-fibrinogen or more low-affinity binding becomes predominant. These findings point at considerable platelet activation during binding experiments. However, arachidonate metabolism ([3H]arachidonate mobilization and thromboxane synthesis) and secretion (['4C]serotonin and ,-thromboglobulin) are about 10% or less of the amounts found under optimal conditions (5 units of thrombin/ml 37°C, stirring). We conclude that PAF-acether induces little platelet activation under binding conditions. The amounts of thromboxane A2 and secreted ADP, however, are sufficient for initiating high-and low-affinity fibrinogen binding via mutually independent mechanisms.
INTRODUCTION
PAF-acether is a potent lipid mediator strongly implicated in the pathogenesis of acute allergic and inflammatory reactions (Pinckard et al., 1982) . It is produced by a variety of cell types such as blood cells (Vargaftig et al., 1981) , endothelial cells (Prescott et al., 1984) and salivary glands (Cox et al., 1981) . In vivo, PAF-acether induces vasodilatation and hypotension (Goldstein et al., 1984) with plasma exudation and it is thought to play an important role in asthma (Page et al., 1984) . Apart from pulmonary hypertension, airway constriction and oedema, intravenous infusion of PAF-acether induces thrombocytopenia and clumping of platelets in the lung capillaries leading to sudden death (Pinckard et al., 1980; Handley et al., 1984) .
In vitro, PAF-acether is a potent activator of platelets and triggers shape change, aggregation and secretion of dense, a-and acid hydrolase granule contents (Chesney et al., 1982; Kloprogge et al., 1983) . Platelet aggregation is known to be mediated via exposure of the glycoprotein Ilb-Illa complex (Gogstad et al., 1982; DiMinno et al., 1983; Bennet & Vilaire, 1979) , which binds fibrinogen in a Ca2+-or Mg2+-dependent reaction (Marguerie et al., 1980) . Exposure of fibrinogen binding sites occurs with different platelet agonists such as ADP, collagen, thrombin, arachidonate, prostaglandin endoperoxides, adrenaline (DiMinno et al., 1983; Bennet & Vilaire, 1979; Marguerie et al., 1980; Kornecki et al., 1981; Marguerie & Plow 1983) and also with PAF-acether (Marguerie & Plow, 1983; Kloprogge & Akkerman, 1984) , but the mechanism by which each agonist exposes the sites is subject to controversy. Marguerie et al. (1980) attribute a central role to ADP, and other agonists would only act via ADP, secreted from the dense granules. Indeed, prostaglandin endoperoxide-induced fibrinogen binding can be completely abolished by ADP scavengers (Morinelli et al., 1983) . On the other hand, Harfenist et al. (1982) demonstrated binding of fibrinogen to degranulated platelets treated with arachidonate, suggesting that other mechanisms play a role. The observation by Peerschke (1982) that adrenaline-induced fibrinogen binding is insensitive to ADP-removing enzymes is in concert with this and also the fact that adrenaline in combination with other agonists produces more binding than adrenaline alone (Peerschke, 1984) indicates that more than one mechanism must be involved.the platelets and metabolized, but these processes are probably irrelevant for platelet activation (Pieroni & Hanahan, 1983) . The present report describes the characteristics of PAF-acether-induced fibrinogen binding and will demonstrate that PAF-acether triggers exposure of the fibrinogen receptor via two mutually independent mechanisms. MATERIALS Chemicals PAF-acether, 1 -O-hexadecyl/octadecyl-2-acetyl-snglycero-3-phosphocholine, purchased from CalbiochemBehring, was dissolved in a Ca2+-free Tyrode's solution (Walsh, 1972) , containing bovine serum albumin (2.5 mg/ml) (Organon Teknika, Oss, The Netherlands) and stored at -70 'C. Forskolin was also obtained from Calbiochem-Behring. The cyclo-oxygenase inhibitors indomethacin and acetylsalicylic acid were from Merck, Sharp & Dohm and Signa respectively. The thromboxane synthetase inhibitor dazmegrel (UK 38.485) was from Pfizer and kindly provided by Dr. H. M. Typer, Department of Clinical Research, Pfizer, Sandwich, Kent, U.K. ADP scavengers used were phosphoenolpyruvate/pyruvate kinase (PEP/PK) and phosphocreatine/ creatine kinase (CP/CPK), both purchased from Boehringer Mannheim. Before use, PK and CPK were dialysed for 14 h (0 'C) against 500 vol. of Ca2+-free Tyrode's solution to remove the contaminating (NH4)2S04.
Preparation of 1251-labelled fibrinogen
Commercially available human fibrinogen (grade L, KABI, Stockholm, Sweden) was dissolved in water (30 mg/ml) in the presence of 10 mM-6-aminohexanoic acid (J. T. Baker Chemical Co.) and 1 mm benzamidine hydrochloride (Sigma). Contaminating fibrin and fibronectin were removed by chromatography on a gelatin-Sepharose 4B column (Pharmacia) (Engvall et al., 1978) . The column was equilibrated and eluted with Ca2+-free Tyrode's solution (pH 7.25) which contained 10 mM-6-aminohexanoic acid and 1 mM-benzamidine hydrochloride. After dialysis four times against 40 vol. of Ca2+-free Tyrode's buffer (8 h, 4 C), the fibrinogen solution was concentrated by dehydration against Sephadex G-200 (Pharmacia) and stored at -70 'C. The protein concentration of the final preparation was determined by the method of Lowry et al. (1951) with bovine serum albumin as a standard. Contamination by Factor VIII-von Willebrand factor was less than 0.015 5% on a molar basis, as measured by an enzyme immunoassay (Cejka, 1982) . Analysis of fibrinogen under reducing conditions according to Laemmli (1970) revealed a pure preparation consisting of Aa-chains (Mr 68000), Bfl-chains (Mr 57000) and y-chains (Mr 49000).
Fibrinogen was radiolabelled with Na125I (Amersham International) by a modified iodogen procedure (Nieuwenhuizen et al., 1980) . Conical 3 ml glass minivials (Chrompack, Middelburg, The Netherlands) were coated with iodogen by transferring 200 ,ul of an iodogen solution (2 mg/100 ml of 1,2-dichloroethane; Merck) and evaporating the solvent under a stream of dry N2. Quantities of 7.9-9.6 nmol of fibrinogen were iodinated with 0.93-1.86 nmol of Na-125I (1 or 2 mCi) in borate buffer [0.125 M-disodium tetraborate (J. T. Baker Chemical Co.)/0.075 M-NaCl (pH 8.2)] containing 3.3 nmol of KI in three subsequent incubations (20 min each, 0°C). The mixture was first dialysed against 500 vol. of non-radioactive KI (10 g/l in 0.15 M-NaCl) at 4°C for 14 h followed by three times against 500 vol. of Tyrode's solution (8 h, 4°C). Incorporation of 1251 into fibrinogen was 78 + 15% (n = 11). The amount of free 1251, measured after precipitating bound 1251 with 200% (w/v) trichloroacetic acid, was 3.4 + 2.1 % of total radioactivity, which remained unchanged for 3 weeks (n = 33). The clottability, measured with 5 units of thrombin/ml (La Roche, Basel, Switzerland), after 10 min at 37°C was 99.2 + 0.8%. The specific activity of the 1251-labelled fibrinogen was 36-222 Ci/mmol. The 1251-labelled fibrinogen solutions were stored at -80°C and used within 3 weeks of preparation.
Platelet isolation
Venous blood from healthy volunteers was collected (with informed consent) into 0.1 vol. of 130 mMtrisodium citrate. The donors claimed not to have taken any medicine during the 10 days prior to blood collection. Gel-filtered platelets were prepared, as decribed elsewhere (Kloprogge et al., 1983) and suspended in Ca2+-free Tyrode's solution containing 0.2% bovine serum albumin and 5 mM-glucose (pH 7.25). The final platelet concentration was (3-4) x 108 cells/ml. In all experiments cell lysis was minimal (< 0.2%, based on the liberation of lactate dehydrogenase). Binding studies with 1251-fibrinogen Duplicate samples of gel-filtered platelets were incubated at 22°C (without stirring), with different amounts of 1251-fibrinogen. Exactly 5 s later the platelets were stimulated with different concentrations of PAF-acether as indicated in the Results section. At different incubation times, triplicate samples (unless stated otherwise) of cell suspension (200 ,ul each) were collected and placed on 100,1 of 20% (w/v) sucrose in Tyrode's solution, in polypropylene tubes (0.4 ml tubes for microsedimentation; Sarstedt, Wien, Austria). Immediately thereafter, the samples were centrifuged in a Beckman Microfuge (12000 g, 22°C) for 2 min and the tips of the tubes were cut off just above the pellet. The number of molecules of fibrinogen bound per platelet was calculated from the specific radioactivity of the 125I-labelled fibrinogen in the pellet fraction compared with the total radioactivity in pellet plus supernatant. The amount of non-specific binding was measured by parallel incubation with 1251-fibrinogen in the absence of PAF-acether. Control studies beteen 3 nm-and 67 nm-1251-fibrinogen have shown that those cells bound as much '251-fibrinogen as did PAF-acether-treated platelets incubated with 1251-fibrinogen in the presence of 100-fold molar excess of non-radiolabelled fibrinogen (at higher concentrations of 1251-fibrinogen, a 100-fold molar excess of non-radiolabelled fibrinogen did not easily dissolve).
Patients
A few experiments were carried out with platelets from a patient with Glanzmann thrombasthaenia, known to be severely deficient in the glycoprotein IIb-Illa complex, the putative binding site for fibrinogen. In another series of experiments platelets were used from a patient with storage pool disease, which are severely deficient in granule-bound ATP and ADP. These platelets contained < 0.02 and 0.18 gmol of granulebound ATP and ADP/1011 platelets, respectively (patient no. 5 in Akkerman et al., 1983 ).
Analysis of platelet responses
Platelets were incubated at 22°C with PAF-acether (0.5 nm or 500 nM), with fibrinogen (40 nm or 500 nM) or with combinations of both. Functional parameters were measured after 30 s, when the cell suspension was stirred (900 rev./min) or after 60 min (non-stirring conditions).
Aggregation of gel-filtered platelets was measured by counting the disappearance of single platelets (Frojmovic et al., 1983; Kloprogge & Akkerman, 1984) , after fixing samples of platelet suspension in 9 vol. of a mixture of cold (O°C) 0.5% glutaraldehyde (Fluka) Thromboxane synthesis was measured with a radioimmunoassay kit for thromboxane B2 (New England Nuclear) after collecting samples of platelet suspensions in 10 vol. of assay buffer (Calbiochem-Behring) (Halushka et al., 1981) . Effect of cyclo-oxygenase inhibitors, thromboxanesynthetase inhibitor and ADP scavengers Gel-filtered platelets were preincubated with the cyclo-oxygenase inhibitors aspirin (1 mM-acetylsalicylic acid) or indomethacin (30 /tM) for 30 min at 37 'C prior to the binding experiments or platelet function studies. For inhibition of thromboxane synthetase, platelets were preincubated (30 min, 37 'C) with 2.5 ,sM-dazmegrel (UK 38.485), a specific thromboxane synthetase inhibitor (Randall et al., 1981) . The influence of ADP scavengers was measured by using 0.28 mM-PEP with 3 units of PK/ml or a combination of 5 mM-CP with 40 units of CPK/ml, added 1 min before the binding studies or the aggregation and secretion experiments. Measurements of I3Hlarachidonate metabolism Arachidonic acid liberation in platelets was measured by incubating platelet-rich plasma at 37 'C for 60 min with 0.01 /ZM-[3H]arachidonic acid (90 Ci/mmol; Amersham International) followed by gel filtration. After incubation of the cell suspension (60 min, 22 'C) with PAF-acether (0.5 or 500 nM) and fibrinogen (1 /M), lipids were extracted according to Bligh & Dyer (1959) . A 1.0 ml sample was mixed with 3.6 ml of chloroform/ methanol (1:2, v/v). Then, water (1.2 ml) and chloro- form (1.2 ml) were added under vigorous shaking and the mixture was centrifuged at 2000 g (22 C) for 1 min to enhance phase separation. The lower phase was collected, concentrated to dryness under N2 flow, and dissolved in 25 ,ul of chloroform/108 platelets. The mixture was chromatographed at room temperature on silica gel 60 (Merck) with the upper phase of ethyl acetate/acetic acid/2,2,4-trimethylpentane (iso-octane)/ water (9:2:5:10, by vol.) according to Hong & Levine (1976) . The lipids were located with 12 vapour. Spots containing free arachidonic acid and its metabolites were scratched off and the radioactivity was counted directly in toluene-based scintillation fluid.
RESULTS
Comparison between binding affinity of native and 125I-labelled fibrinogen Platelets were incubated with 500 nM-PAF-acether for 1 h, in the presence offibrinogen. The ratio of1251-labelled and non-labelled fibrinogen was varied, keeping the total concentration constant (106 nM). Fig. 1 shows that there is no difference in binding of labelled and unlabelled fibrinogen to the platelets. At an equivalent molar ratio of labelled and unlabelled fibrinogen, 50% of the radioactivity of the 125I was associated with the platelets. Equilibrium kinetics of PAF-acether-induced fibrinogen binding
The specific binding of fibrinogen to platelets stimulated with PAF-acether increased with time and reached equilibrium after 30 (at > 1 ,UM fibrinogen, found with 0.5 nM-PAF-acether, 75% with 1 nM-PAFacether whereas maximal binding was found with 100 nM-PAF-acether or more (Fig. 2) . The kinetics of fibrinogen binding to platelets stimulated with 500 nm-PAF-acether are illustrated in Fig. 3 . The specific binding increased in the range between 7.1 nm-and 1 #uM-fibrinogen. Above 1 /iM-fibrinogen, saturation of a finite number of binding sites was reached and no further increase in specific binding could be measured. Scatchard analysis of these data (Fig. 4) Experiments with platelets from a patient with Glanzmann disease failed to show specific fibrinogen binding, both in the high-and low-affinity binding range. Those platelets showed only non-specific binding similar to the non-specific binding of normal platelets (results not shown). The role of endoperoxide/thromboxane formation and ADP secretion in PAF-acether-induced fibrinogen binding
In order to evaluate the role of endoperoxide/thromboxane formation in PAF-acether-induced fibrinogen binding, platelets were pretreated with aspirin or indomethacin and subsequently stimulated with 500 nm-PAF-acether. This treatment led to a slight but significant decrease in specific fibrinogen binding. In contrast, when the role of secreted ADP was investigated by treating platelets with ADP scavengers a considerable decrease in fibrinogen binding was found (Fig. 5) . However, a small but significant amount of fibrinogen remained bound to the platelets. This part could only be abolished by treating the platelets with indomethacin or aspirin. Under those conditions only aspecific binding remained. These findings indicated that the major part of PAF-acether-induced fibrinogen binding was mediated via ADP while the remainder was the result of endoperoxide/thromboxane formation.
These findings were further substantiated in binding studies designed to analyse the two types of fibrinogen binding in more detail. Scatchard plots revealed that aspirin or indomethacin specifically abolished highaffinity fibrinogen binding, leaving the kinetics of low-affinity binding unaltered (Fig. 6a the binding studies were repeated with storage pool deficient platelets, which contained minimal amounts of granule-bound ADP. As expected, these platelets bound much less fibrinogen than did normal cells and Scatchard analysis revealed that binding occurred only in the range of the high-affinity binding sites (Fig. 6c) .
When these experiments were repeated using 0.5 nM-PAF-acether instead of the higher dose, similar results were obtained. Although the amount of specific binding was lower (Fig. 2) Displacement studies with excess of unlabelled fibrinogen have revealed that bound 1251-fibrinogen gradually becomes irreversibly attached to the platelets. Fig. 7 illustrates that initially binding was completely reversible, as measured following forskolin addition (10 #M final concentration), which enabled displacement studies in a range where excess of unlabelled fibrinogen proved unsuitable due to the poor solubility of fibrinogen. At longer incubation times, however, a gradual decrease in reversible binding became apparent leading to 65 + 3% (n = 6) dissociable binding after 60 min, the time used for equilibrium measurements. In order to evaluate whether this property interfered with the characteristics of fibrinogen binding found at equilibrium, binding studies were repeated in the range where complete reversibility was observed. Fig. 8 illustrates the initial binding of 125I-fibrinogen to platelets stimulated with 500 nM-PAF-acether. Again fibrinogen binding was sensitive to indomethacin and ADP scavengers. Pretreatment with indomethacin reduced the binding by about 20% whereas PEP/PK led to an inhibition ofabout 80%. The combination of both inhibitors abolished all specific fibrinogen binding. Although under non-equilibrium conditions the remaining indomethacin-sensitive binding was too small to measure accurately, its contribution could be estimated from the difference between total and PEP/PK-sensitive binding (Fig. 8, broken line) .
A further comparison between fully and partially dissociable fibrinogen binding could be made by calculating the number of binding sites on the basis of binding studies at 5, 10 and 60 min incubation. As demonstrated elsewhere (Kloprogge et al., 1986) , at 500 nM-PAF-acether, exposure of binding sites is complete within 2-5 min and thereafter the sites behave as Vol. 240 (Table 3) . Again no differences are found, suggesting that both types of The strong interference of cyclo-oxygenase/thromboxane synthetase inhibitors and ADP scavengers with the PAF-acether-induced binding offibrinogen suggested that a considerable degree of secretion and arachidonate metabolism took place under the conditions of the binding experiments. Table 4 lists the secretion of dense and a-granule contents as well as the concurrent formation of thromboxane B2 and free [3H]arachidonate (including its metabolites). In the presence of 500 nM-PAF-acether only minimal secretion occurred during a 60 min incubation period, leading to about 10% liberation of dense and ac-granule contents compared with maximal stimulation with thrombin (5 units/ml, 37°C, stirred suspensions). Slightly less secretion took place in the presence of ADP scavengers, whereas the cyclo-oxygenase/thromboxane synthetase inhibitors had no effect on the secretion characteristics. In the absence of inhibitors only about 4 nmol of thromboxane B2/ 1 01 Table 2 . Non-equilibrium kinetics of PAF-acether-induced fibrinogen binding Gel-filtered platelets were incubated with 1 1t_M-2251-fibrinogen, without and with pretreatment with indomethacin. Fibrinogen binding was analysed at 5, 10 and 60 min following stimulation with 500 nM-PAF-acether. From these data the rate constants for association (k+1) and dissociation (k-1) were calculated as described in the text (means+ S.D., n = 24). The rate constants for the difference between untreated and indomethacin-treated platelets were thought to reflect thromboxane A2-mediated binding. Table 4 . Secretion and arachidonate metabolism during PAF-acether-induced fibrinogen binding Platelets were stimulated with 0.5 or 500 nM-PAF-acether in the presence of 1 /LM-fibrinogen with and without the inhibitors defined in the legend of Table 1 under the conditions of the fibrinogen binding studies (22°C, non-stirred). Secretion of dense and a-granule contents was analysed after 60 min by measuring ['4CJserotonin and fl-thromboglobulin, respectively. These data (mean +s.D., n = 6) were expressed as percentages of maximal secretable amounts found extracellularly following 5 min stimulation with 5 units of thrombin/ml at 37°C in stirred suspensions (900 rev./min). Thromboxane B2 formation after 60 min was expressed as nmol/ 1011 cells (n = 4) and the formation of free [3H]arachidonate (including its metabolites, n = 4) after 60 min was expressed as a percentage of the amounts found with 5 units of thrombin/ml (5 min, 37°C).
Secretion (%)
Arachidonate metabolism (% ) binding in platelet aggregation. Under the assumption that stirring did not change the binding characteristics, aggregation (measured as single platelet disappearance) was measured with and without inhibitors, both at 22°C and at 37 'C. Studies at 22 'C showed that aggregation following stimulation with 0.5 and 500 nM-PAF-acether completely depended on low-affinity binding both at high (500 nM) and low (10 nM) concentrations of fibrinogen. Similar findings were obtained at 37 'C when aggregation was measured in the presence of high concentrations of fibrinogen. In contrast, at a fibrinogen concentration of about 100 nm aggregation was slightly slower when high-affinity binding was abolished, suggesting that in this range both types of binding were involved. At lower fibrinogen concentrations, high-affinity binding became increasingly important and between 2 and 10 nM aggregation completely depended on high-affinity fibrinogen binding (Fig. 9) . The different involvement of the two types of binding seen at 22°C and 37°C suggested that the binding characteristics differed between both temperatures. Scatchard analysis revealed a significant decrease in low-affinity binding at 37°C, whereas high-affinity binding remained unchanged. Specifically, the number of low-affinity binding sites decreased 6-fold and became close to the number of high-affinity binding sites (Table 5) .
DISCUSSION
Earlier reports have demonstrated that platelets possess a specific receptor for PAF-acether (Kloprogge & Akkerman, 1984; Valone et al., 1982) . The receptor is saturated within 20 min incubation with 0.5 nM-PAFacether (22°C), which leads to a variety of cellular responses including exposure of fibrinogen binding sites (Kloprogge & Akkerman, 1984) . The present study evaluates the characteristics of PAF-acether-induced fibrinogen binding. Such a study is complicated by the dynamic nature of fibrinogen binding sites. During platelet stimulation these sites shift from an inaccessible state to an exposed state with which fibrinogen can interact. In the absence of fibrinogen, however, the sites undergo a second alteration which makes them again inaccessible to fibrinogen (Kloprogge et al., 1986) . Thus, characterization offibrinogen binding requires fibrinogen to be present at the time of PAF-acether addition as well as optimal exposure of binding sites during the binding studies. As reported elsewhere (Kloprogge et al., 1986) , binding site exposure is complete within 5 min following stimulation with 500 nM-PAF-acether, but takes about 30 min at 0.5 nm or less. The optimal conditions (incubation times of 5-60 min with 500 nM-PAF-acether and 60 min with 0.5 nM-PAF-acether) were therefore chosen for characterization of fibrinogen binding.
A comparison of fibrinogen binding at different concentrations of PAF-acether showed that 30 min incubation with 0.5 nM-PAF-acether induced only twothirds of maximal binding, despite the fact that these conditions are sufficient for complete occupancy of PAF-acether receptors (Kloprogge & Akkerman, 1984) . This effect is only observed within platelets from a single Marguerie et al. (1980 Marguerie et al. ( , 1983 found only a single class of binding sites with characteristics close to our data for low-affinity binding, but these authors left the high-affinity binding range unexplored. Hence, the kinetics of fibrinogen binding induced by PAF-acether seem similar to those provoked by other platelet-stimulating agents, suggesting that despite the diversity among agonists and the mechanisms by which they activate the platelets, all lead to a common step that enables fibrinogen to bind. Studies with intact platelets (Kornecki et al., 1981) as well as with plasma membranes (Fujimura & Phillips, 1983) low-affinity binding. This accords with earlier work (Kornecki et al., 1981) , that demonstrated a similar correlation with optical aggregation. Although at low fibrinogen levels a role for high-affinity binding would be expected, indomethacin treatment had no effect. Probably the high number of low-affinity binding sites compensated for the relative low binding affinity, enabling platelet-platelet interaction even at low levels of fibrinogen. At 37°C, again a major role for low-affinity binding was evident when the fibrinogen concentration was high (> 200 nM). At low fibrinogen levels, however, a role for high-affinity binding became apparent and below 10 nM-fibrinogen aggregation solely depended on high-affinity binding. At this temperature the number of low-affinity binding sites was about 6-fold lower than at 22°C and closer to the range of high-affinity binding sites. Consequently, less compensation for lower binding affinity was possible, enabling high-affinity binding to become involved.
Apart from binding to its receptor, PAF-acether is taken up and metabolized, but it is uncertain whether these processes contribute to platelet activation. Two observations argue against such a role. First, the kinetics of fibrinogen binding found with 0.5 nm and 500 nm-PAF-acether are similar, although only above 1 nM-PAF-acether is receptor occupancy accompanied by uptake and metabolism (Kloprogge & Akkerman, 1984) . Second, the increase in fibrinogen binding found when the PAF-acether concentration is raised from 0.5 to 1.0 nm (where uptake is negligible) is of the same magnitude as found when the dose of PAF-acether is increased from 1 to 100 nm (where uptake and metabolism exceeds receptor binding several-fold; Kloprogge & Akkerman, 1984) . Thus, fibrinogen binding initiated by PAF-acether appears primarily the result of receptor-mediated processes.
In conclusion, the early interaction between PAFacether and platelets triggers exposure of high-affinity fibrinogen binding via arachidonate metabolites, probably thromboxane A2, and low-affinity binding via secreted ADP. Both properties are apparent under equilibrium conditions and during initial binding and appear associated with the glycoprotein lIb-IlIa complex. Whether this reflects two properties of the same binding sites or heterogeneity of sites is at present uncertain. Preliminary studies show that a number of monoclonal antibodies against glycoprotein lb-Illa, as well as the tetrapeptide Gly-Pro-Arg-Pro, interfere with both types of binding, suggesting the involvement of a single type of binding site.
